News from the College

UVM Vaccine Testing Center $3.3 Million Grant from Gates Foundation Featured in Media

September 29, 2016 by Brittany Willette

The Cryptosporidum study team at the UVM Vaccine Testing Center (VTC), which includes Beth Kirkpatrick, M.D., VTC director and UVM professor of medicine; Caroline Lyon, M.D., M.P.H., UVM associate professor of medicine; Christopher Huston, M.D., UVM associate professor of medicine; Catherine Larsson; and Mary Claire Walsh, PA-C, recently received a $3.3 million grant from the Bill & Melinda Gates Foundation to test new therapeutic agents against Cryptosporidium. Read the announcement in Vermont Business Magazine.

TC Cryptosporidum study team members (from left): Beth Kirkpatrick, M.D.; Caroline Lyon, M.D., M.P.H.; Christopher Huston, M.D.; Catherine Larsson; and Mary Claire Walsh, PA-C. (Photo: Marian Miller)

(MARCH 8, 2016) The Cryptosporidum study team at the UVM Vaccine Testing Center (VTC), which includes Beth Kirkpatrick, M.D., VTC director and UVM professor of medicine; Caroline Lyon, M.D., M.P.H., UVM associate professor of medicine; Christopher Huston, M.D., UVM associate professor of medicine; Catherine Larsson; and Mary Claire Walsh, PA-C, recently received a $3.3 million grant from the Bill & Melinda Gates Foundation to test new therapeutic agents against Cryptosporidium. Read the announcement in Vermont Business Magazine.

News about the College

Recent news about the Larner College of Medicine

UVM Vaccine Testing Center $3.3 Million Grant from Gates Foundation Featured in Media

September 29, 2016 by Brittany Willette

The Cryptosporidum study team at the UVM Vaccine Testing Center (VTC), which includes Beth Kirkpatrick, M.D., VTC director and UVM professor of medicine; Caroline Lyon, M.D., M.P.H., UVM associate professor of medicine; Christopher Huston, M.D., UVM associate professor of medicine; Catherine Larsson; and Mary Claire Walsh, PA-C, recently received a $3.3 million grant from the Bill & Melinda Gates Foundation to test new therapeutic agents against Cryptosporidium. Read the announcement in Vermont Business Magazine.

TC Cryptosporidum study team members (from left): Beth Kirkpatrick, M.D.; Caroline Lyon, M.D., M.P.H.; Christopher Huston, M.D.; Catherine Larsson; and Mary Claire Walsh, PA-C. (Photo: Marian Miller)

(MARCH 8, 2016) The Cryptosporidum study team at the UVM Vaccine Testing Center (VTC), which includes Beth Kirkpatrick, M.D., VTC director and UVM professor of medicine; Caroline Lyon, M.D., M.P.H., UVM associate professor of medicine; Christopher Huston, M.D., UVM associate professor of medicine; Catherine Larsson; and Mary Claire Walsh, PA-C, recently received a $3.3 million grant from the Bill & Melinda Gates Foundation to test new therapeutic agents against Cryptosporidium. Read the announcement in Vermont Business Magazine.